Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action
Feldmann, M.; Brennan, F.; Paleolog, E.; Taylor, P.; Maini, R.N.
European Cytokine Network 8(3): 297-300
1997
ISSN/ISBN: 1148-5493 PMID: 9346366 Document Number: 479776
Document emailed within 1 workday
Related Documents
Furst, D.E.; Schiff, M.H.; Fleischmann, R.M.; Strand, V.; Birbara, C.A.; Compagnone, D.; Fischkoff, S.A.; Chartash, E.K. 2003: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) Journal of Rheumatology 30(12): 2563-2571Antoni, C.; Kalden, J.R. 1999: Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis Clinical and Experimental Rheumatology 17(6 Suppl 18: S73-S77
Van Lieshout, A.W.T.; Creemers, M.C.W.; Radstake, T.R.D.J.; Elving, L.D.; van Riel, P.L.C.M. 2008: Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha Journal of Rheumatology 35(5): 938-939
Garcia-Porrua, C.; Gonzalez-Gay, M.A.; Quevedo, V. 2006: Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis? Journal of Rheumatology 33(2): 433; Author Reply 433-4
Straub, R.H.; Härle, P.; Atzeni, F.; Weidler, C.; Cutolo, M.; Sarzi-Puttini, P. 2005: Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy Journal of Rheumatology 32(7): 1253-1258
Dombrecht, E.J.; Aerts, N.E.; Schuerwegh, A.J.; Hagendorens, M.M.; Ebo, D.G.; Van Offel, J.F.; Bridts, C.H.; Stevens, W.J.; De Clerck, L.S. 2006: Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis Clinical and Experimental Rheumatology 24(1): 31-37
Tsybul'ko, S.V.; Baranov, A.A.; Borodin, A.G.; Korshunov, N.I.; Kirdianov, S.Iu. 2001: Tumor necrosis factor-alpha and kidney damage in rheumatoid arthritis Terapevticheskii Arkhiv 73(5): 8-11
Dayer, J.-M. 2002: Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis? Journal of Rheumatology. Suppl 65: 10-15
Tse, S.M.L.; Laxer, R.M.; Babyn, P.S.; Doria, A.S. 2006: Radiologic Improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept Journal of Rheumatology 33(6): 1186-1188
Fabris, M.; Di Poi, E.; D'Elia, A.; Damante, G.; Sinigaglia, L.; Ferraccioli, G. 2002: Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis Journal of Rheumatology 29(1): 29-33
Pachot, A.; Arnaud, Béatrice.; Marrote, H.; Cazalis, M-Angélique.; Diasparra, J.; Gouraud, A.; Mougin, B.; Miossec, P. 2007: Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response Journal of Rheumatology 34(11): 2158-2161
Rémy, A.; Avouac, J.; Gossec, L.; Combe, B. 2011: Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis Clinical and Experimental Rheumatology 29(1): 96-103
Sundrarjun, T.; Komindr, S.; Archararit, N.; Dahlan, W.; Puchaiwatananon, O.; Angthararak, S.; Udomsuppayakul, U.; Chuncharunee, S. 2004: Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-alpha and soluble tumour necrosis factor receptor p55 in active rheumatoid arthritis Journal of International Medical Research 32(5): 443-454
Jin, D.; Tie, N.; Liu, J.; Zhao, L.; Hao, D.; Zhao, Y. 2015: Investigation of the risk of hepatitis B virus reactivation in arthritis patients undergoing anti-tumour necrosis factor alpha therapy Zhonghua Nei Ke Za Zhi 54(4): 313-316
den Broeder, A.A.; Creemers, M.C.W.; Fransen, J.; de Jong, E.; de Rooij, D-Jan.Ram.; Wymenga, A.; de Waal-Malefijt, M.; van den Hoogen, F.H.J. 2007: Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study Journal of Rheumatology 34(4): 689-695
Tanaka, N.; Kojima, K.; Muro, M.; Naomoto, Y.; Moreira, L.F.; Orita, K. 1995: Anti-proliferative and cytokinetic effects of tumor necrosis factor-alpha, interferon-alpha and 5-fluorouracil on a human tumor xenograft Anticancer Research 15(5b): 1949-1952
Lans, T.E.; Van Horssen, R.; Eggermont, A.M.M.; Ten Hagen, T.L.M. 2004: Involvement of endothelial monocyte activating polypeptide Ii in tumor necrosis factor-alpha-based anti-cancer therapy Anticancer Research 24(4): 2243-2248
Kaneko, H.; Yamada, H.; Mizuno, S.; Udagawa, T.; Kazumi, Y.; Sekikawa, K.; Sugawara, I. 1999: Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice Laboratory Investigation; a Journal of Technical Methods and Pathology 79(4): 379-386
Zochling, J.; Sieper, J.; van der Heijde, Désirée.; Braun, Jürgen.; Weber, U.; Rudwaleit, M.; Leirisalo-Repo, M.; Collantes-Estévez, E.; van der Horst-Bruinsma, I.; Géher, P.; Kvien, T.; deVlam, K.; l Ostergaard, M.; Maksymowych, W. 2008: Development of a core set of domains for data collection in cohorts of patients with ankylosing spondylitis receiving anti-tumor necrosis factor-alpha therapy Journal of Rheumatology 35(6): 1079-1082
Archer, D.F.; DeSoto, K.R.; Baker, J.M. 1999: Interleukin-6 and tumor necrosis factor-alpha concentrations in the intrauterine cavity of postmenopausal women using an intrauterine delivery system releasing progesterone. a possible mechanism of action of the intrauterine device Contraception 59(3): 175-179